Predictive value for coronary heart disease of baseline high-density and low-density lipoprotein cholesterol among Fredrickson type IIa subjects in the Helsinki Heart Study

Manninen, Vesa; Koskinen, Pekka; Mänttäri, Matti; Huttunen, Jussi K.; Canter, David; Frick, Heikki

doi:10.1016/0002-9149(90)90566-j

Cited by 10 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRP levels generally correlate with the severity of CAD. Despite a large body of evidence for the prognostic value of HDL-C [4,[13][14][15][16][17][18][19][20][21] and CRP [22] for future cardiovascular events, to our knowledge this is the largest study investigating their independent association with the prevalence and severity of angiographically evaluated CAD.…”

Section: Discussionmentioning

confidence: 99%

High‐density lipoprotein cholesterol, C‐reactive protein, and prevalence and severity of coronary artery disease in 5641 consecutive patients undergoing coronary angiography

Alber

Wanitschek

Waha

et al. 2008

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

High‐density lipoprotein cholesterol, C‐reactive protein, and prevalence and severity of coronary artery disease in 5641 consecutive patients undergoing coronary angiography

Alber

Wanitschek

Waha

et al. 2008

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Follow-up of the Framingham Heart Study revealed that HDL-C levels were inversely related to the incidence of myocardial infarction, 14 and in the Helsinki Heart Study, HDL-C levels were predictive of future coronary artery disease risk in patients with Type IIa hyperlipoproteinemia. 15 Based on an analysis of four major trials, Gordon et al found that the risk of CHD was reduced by 2 to 3% for every 1 mg/dl increase in HDL-C. 16 More recently, the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) provided evidence that raising HDL-C and lowering TG in patients with low levels of HDL-C and normal or near normal LDL-C levels can substantially reduce the risk of nonfatal myocardial infarction and CHD-related death. 17 All statins produce dose-dependent reductions in the plasma levels of LDL-C and TG.…”

Section: Discussionmentioning

confidence: 99%

Differential effects of simvastatin and atorvastatin on high‐density lipoprotein cholesterol and apolipoprotein A‐I are consistent across hypercholesterolemic patient subgroups

Davidson

Ose

Fröhlich

et al. 2003

Clinical Cardiology

View full text Add to dashboard Cite

SummaryBackground: In addition to lowering plasma levels of lowdensity lipoprotein cholesterol (LDL-C), statins also raise high-density lipoprotein cholesterol (HDL-C).Hypothesis: Recent studies have shown that treatment with simvastatin results in larger increases in HDL-C than those seen with atorvastatin. The results of three clinical studies are analyzed, comparing the effects of simvastatin and atorvastatin on HDL-C and apolipoprotein A-I (apo A-I) in the total cohort and in several subgroups of hypercholesterolemic patients. The three studies were all multicenter, randomized clinical trials that included simvastatin (20-80 mg) and atorvastatin (10-80 mg) treatment arms. The subgroup analyses performed were gender; age (< 65 and ≥ 65 years); baseline HDL-C (male: <40 or ≥40 mg/dl; female: < 45 or ≥45 mg/dl), baseline LDL-C (< 160 or ≥ 160 mg/dl), and baseline triglycerides (< 200 or ≥ 200 mg/dl).Results: Both drugs produced similar increases in HDL-C levels at low doses; however, at higher drug doses (40 and 80 mg), HDL-C showed a significantly greater increase with simvastatin than with atorvastatin (p < 0.05 to < 0.001). Therefore, while HDL-C remained consistently elevated across all doses of simvastatin, there appeared to be a pattern of decreasing

show abstract

Cholesterol Testing in Young Adults

Cd¹

1993

JAMA

View full text Add to dashboard Cite

teed assistance at state-supported colleges.These prescriptions would require greater expenditures in the recommended areas. At issue is whether we want to pay now or pay later. We can pay more for strategies that make an investment in our children's health and future, or we can continue to pay for costly intervention and treatment of pre¬ ventable problems. Our greatest chance of improving the health status of our adolescents lies in early and ongoing protection and promo¬ tion of their health and development. As a society, we must value our children enough to make a universal commitment to their future. With a consensus of values and a collaboration of effort, we can assist our adolescents in making a successful transition to adulthood.

show abstract

Predictive value for coronary heart disease of baseline high-density and low-density lipoprotein cholesterol among Fredrickson type IIa subjects in the Helsinki Heart Study

Cited by 10 publications

References 9 publications

High‐density lipoprotein cholesterol, C‐reactive protein, and prevalence and severity of coronary artery disease in 5641 consecutive patients undergoing coronary angiography

High‐density lipoprotein cholesterol, C‐reactive protein, and prevalence and severity of coronary artery disease in 5641 consecutive patients undergoing coronary angiography

Differential effects of simvastatin and atorvastatin on high‐density lipoprotein cholesterol and apolipoprotein A‐I are consistent across hypercholesterolemic patient subgroups

Cholesterol Testing in Young Adults

Contact Info

Product

Resources

About